NEXGEL's Acquisition of Celularity Products to Triple Revenue
NEXGEL's acquisition of Celularity's biomaterials portfolio is expected to significantly boost annual revenue to around $35 million and make the company immediately profitable. This strategic move positions NEXGEL as a strong player in the regenerative medicine market, likely enhancing shareholder value in the near term.
View signal analysis